Effects of interleukin-6 blockade on the development of autoimmune thyroiditis in nonobese diabetic mice

References

• Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 1998; 20: 247–259
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243–1254
   PubMed Web of Science ®Google Scholar
• Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Murashima A, Tsunasawa S, Sekiyama F, Kishimoto T. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988; 18: 1797–1801
   PubMed Web of Science ®Google Scholar
• Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto T. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74: 1360–1367
   PubMed Web of Science ®Google Scholar
• Gross V, Andus T, Caesar I, Roth M, Schölmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102: 514–519
   PubMed Web of Science ®Google Scholar
• Mihara M, Nishimoto N, Yoshizaki K, Suzuki T. Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice. Immunol Lett 2002; 84: 223–229
   PubMed Web of Science ®Google Scholar
• Okazaki M, Yamada Y, Nishimoto N, Yoshizaki K, Mihara M. Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett 2002; 84: 231–240
   PubMed Web of Science ®Google Scholar
• Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T, Takeda Y, Ohsugi Y. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998; 41: 2117–2121
   PubMed Web of Science ®Google Scholar
• Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K-I, Nishimoto N, Kishimoto T, Yoshizaki K, Ohsugi Y. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002; 20: 304–311
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000; 164: 4878–4882
   PubMed Web of Science ®Google Scholar
• Champion BR, Cooke A, Rayner DC. Thyroid autoimmunity. Curr Opin Immunol 1992; 4: 770–778
   PubMedGoogle Scholar
• Paschke R, Schuppert F, Taton M, Velu T. Intrathyroidal cytokine gene expression profiles in autoimmune thyroiditis. J Endocrinol 1994; 141: 309315
   Google Scholar
• Ajjan RA, Watson RF, McIntosh RS, Weetman AP. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clin Exp Immunol 1996; 105: 523–528
   PubMed Web of Science ®Google Scholar
• Matsumura M, Banba N, Motohashi S, Hattori Y. Interleukin-6 and transforming growth factor-β regulate the expression of monocyte chemoattractant protein-1 and colony-stimulating growth factors in human thyroid follicular cells. Life Sci 1999; 65: 129–135
   Google Scholar
• Yamazaki K, Yamada E, Kanaji Y, Shizume K, Wang D-S, Maruo N, Obara T, Sato K. Interleukin-6 (IL-6) inhibits thyroid function in the presence of soluble IL-6 receptor in cultured human thyroid follicles. J Clin Endocrinol Metab 1996; 137: 4857–4863
   Google Scholar
• Tominaga T, Yamashita S, Nagayama Y, Morita S, Yokoyama N, Izumi M, Nagataki S. Interleukin 6 inhibits human thyroid peroxidase gene expression. Acta Endocrinol 1991; 124: 290–294
   PubMedGoogle Scholar
• Hashimoto H, Igarashi N, Miyawaki T, Sato T. Effects of tumor necrosis factor-α, interleukin-1β, and interleukin-6 on type I iodothyronine 5′-deiodination in rat thyroid cell line, FRTL-5. J Interf Cytokine Res 1995; 15: 367–375
   PubMedGoogle Scholar
• Bartalena L, Brogioni S, Grasso L, Martino E. Interleukin-6 and the thyroid. Eur J Endocrinol 1995; 132: 386–393
   PubMed Web of Science ®Google Scholar
• Damotte D, Colomb E, Cailleau C, Brousse N, Charreire J, Carnaud C. Analysis of susceptibility of NOD mice to spontaneous and experimentally induced thyroiditis. Eur J Immunol 1997; 27: 2854–2862
   PubMed Web of Science ®Google Scholar
• Tani J-I, Mori K, Hoshikawa S, Nakazawa T, Satoh J, Nakagawa Y, Ito S, Yoshida K. Prevention of lymphocytic thyroiditis in iodide-treated non-obese diabetic mice lacking interferon regulatory factor-1. Eur J Endocrinol 2002; 147: 809–814
   PubMed Web of Science ®Google Scholar
• Jin Z, Mori K, Fujimori K, Hoshikawa S, Tani J-I, Satoh J, Ito S, Satomi S, Yoshida K. Experimental autoimmune thyroiditis in non-obese diabetic mice lacking interferon regulatory factor-1. Clin Immunol 2004; 113: 187–192
   PubMedGoogle Scholar
• Saboori AM, Rose NR, Butscher WG, Burek CL. Modification of a nonincinerative method for determination of iodine in iodoproteins. Anal Biochem 1993; 214: 335–338
   PubMedGoogle Scholar
• Kong Y, David CS, Giraldo AA, Elrehewy M, Rose NR. J Immunol 1979; 123: 15–18
   PubMed Web of Science ®Google Scholar
• Kaiser P, Rothwell L, Vašíček D, Hala K. A role for IL-15 in driving the onset of spontaneous autoimmune thyroiditis?. J Immunol 2002; 168: 4216–4220
   PubMedGoogle Scholar
• Mori K, Yoshida K, Tani J-I, Nakagawa Y, Hoshikawa S, Ozaki H, Ito S. Effects of angiotensin II blockade on the development of autoimmune thyroiditis in nonobese diabetic mice. Clin Immunol 2008; 126: 97–103
   PubMedGoogle Scholar
• Tada Y, Ho A, Matsuyama T, Mak TW. Reduced incidence and severity of antigen-induced autoimmune disease in mice lacking interferon regulatory factor-1. J Exp Med 1997; 185: 231–238
   PubMed Web of Science ®Google Scholar
• Sagawa K, Nagatani K, Komagata Y, Yamamoto K. Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice. Arthritis Rheum 2005; 52: 1920–1928
   PubMedGoogle Scholar
• Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V, Ciliberto G. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187: 461–468
   PubMed Web of Science ®Google Scholar
• Mendel I, Katz A, Kozak N, Ben-Nun A, Revel M. Interleukin-6 functions in autoimmune encephalomyelitis: A study in gene-targeted mice. Eur J Immunol 1998; 28: 1727–1737
   PubMed Web of Science ®Google Scholar
• Tanaka T, Katada Y, Higa S, Fujiwara H, Wang W, Saeki Y, Ohshima S, Okuda Y, Suemura M, Kishimoto T. Enhancement of T helper2 response in the absence of interleukin (IL-) 6; an inhibition of IL-4-mediated T helper2 cell differentiation by IL-6. Cytokine 2001; 13: 193–201
   PubMedGoogle Scholar
• Toyoda H, Formby B. Contribution of T cells to the development of autoimmune diabetes in the NOD mouse model. BioEssays 1998; 20: 750–757
   PubMedGoogle Scholar
• Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, Braverman LE, Roti E. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab 1996; 81: 2976–2979
   PubMed Web of Science ®Google Scholar
• Minelli R, Girasole G, Pedrazzoni M, Giuliani N, Schianchi C, Giuberti T, Braverman LE, Salvi M, Roti E. Lack of increased interleukin-6 and soluble IL-6 receptor concentrations in patients with thyroid diseases following recombinant human interferon α therapy. J Invest Med 1996; 44: 370–374
   PubMedGoogle Scholar
• Bartalena L, Brogioni S, Grasso L, Rago T, Vitti P, Pinchera A, Martino E. Interleukin-6: A marker of thyroid-destructive processes?. J Clin Endocrinol Metab 1994; 79: 1424–1427
   PubMed Web of Science ®Google Scholar